© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Back in the 1960s, scientists working with Streptomyces spectabilis discovered spectinomycin, which soon caught the eyes of researchers because of its activity against certain bacteria, especially Neisseria gonorrhoeae. This antibiotic didn’t grow out of thin air; it resulted from a lot of trial and error, growing microbes in fermentation tanks, and then testing what came out. Many antibiotics from that period emerged in a similar way: dig through the world’s soil, find a microbe, see if it kills bacteria, then figure out how to produce it at scale. Spectinomycin didn’t get the same broad attention as penicillins or tetracyclines, but it built a niche for itself, especially in treating infections where resistance had narrowed other options. Later, forming it as the hydrochloride pentahydrate salt made it easier to handle and dose in clinical settings, and that form became the standard for manufacturing and therapeutic use.
Spectinomycin Hydrochloride Pentahydrate often gets mentioned in the context of injectable antibiotics for gonorrhea, particularly when allergies rule out other drugs. It appears as a white or almost-white, crystalline powder, easy to dissolve in water, which fits the bill for hospital use because injections call for quick, clear solutions. As someone who’s worked near pharmaceutical development labs, the packaging is typically robust for moisture sensitivity—dry pouches, silica packets, the whole nine yards. Many pharmaceutical manufacturers around the world recognize the utility it has for fast, direct intervention in severe infections, especially where oral drugs fall short due to absorption problems or resistance.
Spectinomycin Hydrochloride Pentahydrate displays moderate stability if kept away from strong light and high heat. It is a polyhydroxy cyclitol amine—an unusual structure by antibiotic standards—which helps define its solubility and biological activity. Its crystals hydrate with five water molecules per molecule of spectinomycin hydrochloride. With a molecular formula of C14H24N2O7•HCl•5H2O, it sports a molecular weight north of 495 g/mol. Exposure to excessive heat can degrade the molecule, so manufacturers use cool, dry storage. The hydrochloride salt version packs better water solubility, which can be critical for both research formulation and for injectable products in hospitals.
Each batch usually arrives with a certificate of analysis that answers for its purity, sometimes greater than 98% by HPLC. No one wants trace heavy metals or residual solvents in a finished drug, so specs cap those at parts per million. Pharmacopoeias require compliance with standards around pH (usually in the 3.5–5.5 range), loss on drying to check for too much water, and a near-neutral or slightly acidic solution. Labels spell out the batch, expiration date, recommended storage temps (generally 2–8 °C), and a stern warning to protect from light. Unopened vials last over a year if kept cool and dry, which boosts reliability in the clinic. Each vial also prints its dosing strength to avoid confusion in fast-moving emergency rooms.
Production stems from fermentation. Streptomyces spectabilis works as the biological engine, grown in vats filled with nutrients. After a stretch of cultivation, the broth gets filtered, and the crude antibiotic extracted. Purification steps follow—sometimes solvent extraction, sometimes column chromatography, depending on the scale—before converting to the hydrochloride salt and crystallizing. The pentahydrate form forms naturally during crystallization from aqueous solutions under controlled conditions. Yield and purity depend on good process control, starting with strain selection through fermentation timing to the exact solvent and precipitation techniques used. Gaps in any step can tank the yield, foul the purity, or lengthen purification for weeks.
Spectinomycin tends not to undergo a huge range of chemical modifications in pharmaceuticals, since the molecule itself delivers a tight balance of activity and low human toxicity. Synthetic chemists have tried tweaks—acetylation or alkylation of certain hydroxyl groups—to probe for broader antibacterial activity or to slow bacterial resistance, but most analogues lose effectiveness or grow toxic. In the lab, hydrolysis breaks the molecule apart if exposed to strong acids or bases, but typical handling keeps those risks at bay. Researchers occasionally leverage labeling or conjugation reactions on the amine group for detection or imaging in experimental systems, but for clinical use, the parent compound’s salt is king.
Pharmacists and scientists sometimes call it by shorter names, such as actinospectacin or by simple variants—Spectinomycin HCl Pentahydrate, spectinomycin hydrochloride, or even just “spectinomycin” in clinical shorthand. International brands differ. You’ll spot it sold as Trobicin and other regional generic equivalents for injection. Another synonym in chemical registries is (2R,3S,5R,6S)-5,6-dihydroxy-3-(hydroxymethyl)-2-piperidinyl-1,3,4-trihydroxycyclohexane hydrochloride pentahydrate, though few outside regulatory filings use the full string. In the API trade, the CAS number—22189-32-8—keeps it clear when talking internationally with manufacturers or regulators.
Spectinomycin Hydrochloride Pentahydrate needs careful handling—recent audits of manufacturing plants highlight the focus on high standards for contamination, cross-exposure, and employee protection. The powder can irritate airways if inhaled, and repeated exposure can lead to allergic reactions, so protective masks and gloves come standard. In hospitals, injection protocols prioritize sterile technique since contamination risks can mean patient infections. The WHO and several national agencies require batch traceability and robust pharmacovigilance to spot rare allergic responses or unexpected side effects. Production lines comply with cGMP requirements—every vessel, pump, and pipeline goes through cycle after cycle of validation and swab-testing to avoid cross-contamination. Every product lot includes documentation on microbial control and endotoxin levels.
Most spectinomycin hydrochloride pentahydrate still heads towards infectious disease clinics. Doctors inject it for gonorrhea, especially in cases where patients have allergies to β-lactams or tetracyclines. In the past, it also filled gaps left by resistant E. coli or Salmonella in research settings or animal husbandry, but most of today’s clinical demand comes from its last-resort status when resistance has stymied other treatments. Outside direct patient care, some genetics labs leverage it as a selection antibiotic in cloning, favoring strains not affected by spectinomycin resistance genes.
Designing better antibiotics always feels like chasing a moving target. Drug developers working with spectinomycin derivatives try to counteract emerging resistance—bacteria constantly evolve, so research runs on stealing a march on new resistance genes. Modifying spectinomycin itself has proved tricky; it sits in a precise structural sweet spot. Some groups look to conjugate spectinomycin with other drugs, enhancing uptake or limiting resistance, though regulatory challenges mount for new chemical entities. There’s active interest in using it alongside other last-resort antibiotics as combination therapy, trying to lower the odds of resistance developing during treatment. Laboratories keep turning over the question: can new delivery methods, like nanoparticles or depot injections, extend spectinomycin’s range or lengthen its action without spiking side effects?
Comparing spectinomycin to other aminocyclitols, it performs well from a patient safety perspective. Studies reveal injection site pain and mild kidney impact as the most common complaints, but serious events remain rare. Long-term animal trials at high doses show little evidence of cumulative toxicity, and the molecule doesn’t build up in the body over time when kidneys function normally. Still, babies and people with kidney dysfunction get extra caution due to altered drug clearance. Surveillance studies since the 1980s confirm that life-threatening hypersensitivity remains unusual, though cases can crop up in unpredictable ways across diverse gene pools. Surveillance continues in most health systems to spot unexpected patterns.
The trend toward drug-resistant infections pushes the value of spectinomycin back into the clinical spotlight, especially in lower-income areas where gonorrhea morphs rapidly and older treatments falter. Innovators in pharmaceutical technology can look toward reformulation: slow-release injectables, new salt forms, or dual-therapy vials for blunt-force attack on infections. Another possibility—a return to basic science to explore analogues that escape existing bacterial defenses, drawing insights from microbial ecology and genomics to predict which chemical changes could outpace resistance trends. Governments and global health groups might prioritize safer and streamlined manufacturing to keep costs within reach for essential treatment settings. For any pharmaceutical company or clinic invested in fighting resistant infections, spectinomycin hydrochloride pentahydrate stands as a proven workhorse, and its role will only grow as the world faces tougher bugs and fewer new antibiotics in the pipeline.
Spectinomycin Hydrochloride Pentahydrate holds a particular spot in medicine for fighting off specific infections. Many people have never heard of it, yet doctors keep it in their arsenal for treating certain cases of gonorrhea, especially when other antibiotics like penicillin run into resistance. Spectinomycin steps up when first-line treatments drop out, a bit like calling in a reliable backup. Over the years, antibiotic resistance has turned into a real headache for healthcare workers and patients. Resistant gonorrhea doesn’t just make people sicker; it strains health systems, especially in places where older drugs have stopped working.
Spectinomycin comes from the class of aminocyclitol antibiotics. Unlike some broad-spectrum drugs that take a scattershot approach, spectinomycin gets straight to the point: it stops bacteria from building proteins, halting their growth. This selective action means the body’s own systems aren’t disrupted as much, which can spare patients from certain side effects. Still, it’s only part of the solution. With gonorrhea cases rising globally and about half a million new cases of multidrug-resistant gonorrhea reported each year, as estimated by the World Health Organization, the need for alternatives like spectinomycin couldn't be more urgent.
In my time following public health updates, the panic around superbugs hasn’t died down. Some treatments simply don’t work anymore—resistance develops faster than many new drugs reach the market. So, when spectinomycin steps in, it keeps doors open. For people allergic to penicillin, this drug makes the difference between getting better and running out of options. For doctors in clinics who see a tough infection turn up, they’re not left empty-handed.
Ongoing access troubles keep coming up. Spectinomycin has fallen out of favor in some places, mainly because the demand for treating gonorrhea dropped a bit with the arrival of newer medications. As a result, manufacturing slowed and the price went up in some regions. This creates a situation: the drug works, yet it’s hard to get. On top of that, spectinomycin doesn’t treat all kinds of infections. It won’t work against syphilis or other common sexually transmitted diseases, and the Centers for Disease Control and Prevention only recommends it for folks who absolutely can’t use standard therapies.
Access to a full toolkit gives healthcare workers more ways to respond. Keeping production of spectinomycin on stable ground would prevent shortages. Regulatory agencies can also play a part by recognizing it as a critical medicine. Global response doesn’t stop there: information campaigns about antibiotic resistance might sound repetitive, but they can help slow down misuse. Doctors need time and trust from their patients to make smart antibiotic choices, and people deserve explanations that make sense.
Spectinomycin Hydrochloride Pentahydrate doesn’t carry the fame of penicillin, yet it still holds value. With resistance on the rise, even old tools gain new importance. Investing in medical supply chains, supporting ongoing research, and focusing public attention on these issues gives us a chance to stay a step ahead of the bugs.
Knowing the right amount of any antibiotic means the difference between real progress and wasted time. Doctors and pharmacists often see the harm that comes from cutting corners or guessing. Too little, and bacteria keep growing; too much, and side effects hit hard. With spectinomycin hydrochloride pentahydrate, the right amount means a patient feels better sooner, not just “treated.”
Spectinomycin hydrochloride pentahydrate gained its reputation in treating gonorrhea. Most published material and leading health authorities stick to a single intramuscular injection—usually 2 grams as a one-time, deep-gluteal shot for adults and teens. Researchers landed on this figure not by guesswork, but after seeing strong track records clearing infections without inviting serious side effects. No multi-day pill bottle. No long-form course. Just one tough shot for an urgent problem.
For kids over two years old, doctors use body weight to adjust the dose—40 mg for every kilogram, capping at 2 grams per shot. Parents watching their children recover from a tough infection know why exact dosing matters. Since young bodies handle medicines differently, precise measurement gets rid of the bug but keeps kids safe from harms that come with overmedication.
Anyone working in emergency rooms, clinics, or pharmacies sees patients hoping for fast answers. There aren’t many shortcuts with antibiotics. People with kidney or liver problems may need extra caution, though for spectinomycin, there’s actually less cause for alarm, since the body gets rid of this drug mainly through urine. Still, good medical teams dig deeper for patients with unusual histories or past reactions.
Allergies rarely pop up with spectinomycin, but letting a provider know about any previous drug reactions always helps. After an injection, mild discomfort or redness at the site may show up, and mild fever or nausea has come up in some reports. These issues tend to pass. If symptoms turn serious, getting a doctor’s attention is a must.
Hospitals and clinics face a real threat from bacteria that find ways to dodge antibiotics. In a world with stubborn gonorrhea strains, sticking to recommended doses keeps these bugs from learning new tricks. Using too little, changing the rules, or not finishing a dose leaves room for bacteria to come back tougher. Responsible use protects everyone—patients today and whole communities tomorrow.
A well-chosen dose gets a patient to recovery with fewer setbacks. The urge to do something extra for peace of mind is strong, but too much antibiotic only drains wallets and disrupts more than just bacteria. Education matters: patients can ask questions, double-check needle size, and speak up about their past health history.
It’s worth recognizing that proper dosing, based on the most trusted sources and years of careful study, remains the anchor of safe antibiotic care. Spectinomycin hydrochloride pentahydrate proves that sometimes, one precisely measured step is enough.
Spectinomycin Hydrochloride Pentahydrate cuts down on stubborn bacterial infections. It’s part of the toolkit in hospitals treating certain types of gonorrhea, especially when people can’t handle common antibiotics like penicillin. But every medicine walks a fine line between helping and hurting, and this one doesn’t get a free pass.
Talk to folks in infectious disease wards or anyone with a pharmacy background and you’ll hear the same thing: No injection is harmless. Some people receiving this drug feel mild discomfort at the injection site—pain, redness, even a hardened lump. A few hours in, soreness may creep in, and some get a little swelling. Sometimes that pain seems like a small price to pay for clearing out a tough infection.
The body’s system can react in different ways, and those reactions don’t always stay local. Upset stomach, nausea, or the urge to vomit show up in some. That’s not unique to this medicine—many antibiotics disturb gut balance, killing helpful bacteria as collateral damage. Diarrhea sometimes follows, and for people already feeling weak, this can drag out recovery more than expected.
Allergies don’t knock politely. Occasional folks react with skin rash, hives, or itching, sending signals the immune system doesn’t want the drug around. Rare cases escalate: shortness of breath or swelling in the lips, tongue, or face. These symptoms raise alarms and often send patients back to the emergency department for help.
Once in a while, dizziness, headache, or fever crop up. I’ve seen patients blame exhaustion, but you have to wonder if the medicine tips the scale. With my own family member, an unexpected spike in temperature after antibiotic use left us second-guessing; we needed a doctor’s input to sort out whether to stop or switch prescriptions.
Evidence carries weight in medicine, and the numbers shape decisions. Reports from the FDA include local reactions in over 7% of patients. Gastrointestinal complaints come in at a lower rate, but still high enough to mention. Medical journals lay out rare complications. Kidney trouble and serious allergic reactions stand out, sparking warnings in prescribing information for clinicians.
Doctors point out spectinomycin doesn’t drag quite as many long-term risks as some antibiotics. No hearing loss, nerve damage, or blood problems commonly linked with other heavy hitters. Resistance remains a worry, though, especially in places where the infection lingers or returns. Overuse always sets the stage for less future treatment power.
Clear communication between patient and doctor does a lot of the heavy lifting. Inform health providers about drug allergies and ongoing health issues. Pharmacists play a role too, checking for unsafe combinations with other medicines. Complete the full course, unless the side effects cross a line, and circle back for follow-up if problems flare up.
Asking about previous reactions, different options, or signs to watch for helps catch trouble early. Clinics with clear protocols pick up on warning signs faster, protecting both patients and staff.
Spectinomycin Hydrochloride Pentahydrate doesn’t show up unless it’s needed. For people stuck with an infection stubborn to front-line drugs, it’s a lifeline. Knowing the common side effects—local discomfort, stomach issues, and rare allergies—can steer patients and providers toward safer outcomes. No medicine solves every problem, but careful choices keep the balance in our favor.
Spectinomycin Hydrochloride Pentahydrate stands as a critical antibiotic for certain resistant infections, and its effectiveness starts long before it meets a patient. Everything begins with storage. The stability of this material depends on more than a casual shelf placement.
Based on my own work with sensitive compounds, a steady routine pays off. Spectinomycin hydrochloride pentahydrate should stay in a cool, dry spot—think 2°C to 8°C, which matches the temperature in most laboratory fridges. Heat chips away at its power, moisture speeds up degradation, and direct sunlight or bright indoor lighting nudges chemical breakdown along much faster than people expect.
Pharmacists and lab techs know that pentahydrate forms spell a warning: water loves to creep in or out, and once humidity gets in the jar, the whole batch can lose potency or bake into stubborn lumps. Keeping the cap screwed tightly matters every time, not just for good housekeeping—too often, a short lapse ruins an entire supply. I learned this lesson early, after losing a costly stockpile of reagent to a humid storeroom window left open for one weekend.
Add in a working-quality desiccant, tucked neatly into storage containers, and humidity stays in check. Skipping this step might seem fine in the short run, but studies show antibiotic degradation accelerates fast once moisture rises above 60%. One overlooked rainy day, and nobody wants to guess if the next treatment dose still packs the intended punch.
Spectinomycin breaks down under strong light. Clear bottles on well-lit counters tempt damage, so opaque packaging does more than look professional; it blocks UV and visible light. Some hospitals wrap material in aluminum foil, and these folks don’t do it for style. Light-induced changes in antibiotics often slip by unnoticed until a batch goes through quality testing—and fails.
It sounds basic, but hands bring in bacteria, mold spores, and plenty of uninvited trouble. Only open bottles in clean work areas, and always scoop powder with sanitized tools. I’ve seen more than one product recall start in a hasty, cluttered workspace. Small mistakes in sterile handling become headlines when resistant infections appear.
Every vial should carry not just a name and lot number but also an expiration date and storage instructions. Jumbled labels—or no label at all—invite confusion. Storage logs fill gaps in memory and prove helpful during safety audits. After one close call with expired reagents, I stick to a simple system: date received, date opened, and a visible reminder of the ideal storage range. This keeps surprises at bay and supports the safety chain.
Keeping Spectinomycin Hydrochloride potent is a group effort. Regular staff training, surprise audits, and posted reminders all add up. Mistakes often happen not from lack of rules but lapses in routine. Each new batch offers another chance to get the basics right.
With antibiotics so closely tied to patient outcomes, storing Spectinomycin Hydrochloride Pentahydrate isn’t just a detail. It sets the stage for real-world results. Every step matters, from fridge to pill bottle. The small details save lives and dollars—no one wants to see valuable medicine wasted because the storage was sloppy.
Spectinomycin Hydrochloride Pentahydrate isn’t the kind of antibiotic people keep in a home medicine cabinet. Used to tackle stubborn bacterial infections, this compound often comes up in hospitals rather than a local pharmacy. My time working alongside prescribing doctors taught me there’s usually quite a bit of checking and double-checking before they go for antibiotics reserved for specific infections, especially when resistance is on the rise.
Across countries, restrictions on antibiotics like spectinomycin aren’t arbitrary. These rules step in to slow down resistance. Health authorities in the U.S., Europe, and most parts of Asia require a script from a licensed provider. Without supervision, misuse happens fast. Folks tend to take antibiotics too soon, too often, or not long enough, inviting bacteria to adapt. After years around the pharmacy trade, I saw firsthand people pushing for powerful antibiotics—but also saw infections bounce back, tougher than before, when guidelines went ignored.
It’s easy for people to assume online suppliers or friends in the medical field mean fast, safe access. Thing is, improper use of spectinomycin can set off side effects—rashes, dizziness, gut trouble—not to mention allergic reactions. Even more serious is missing the mark: giving spectinomycin for the wrong infection, or at the wrong dose, leaves the real cause untreated and thriving. That’s especially a worry for vulnerable folks, like children or those with kidney conditions.
Minimizing resistance takes more than rules. My years talking to patients showed me many believe antibiotics deliver a cure-all, but most coughs and viral bugs won’t budge with antibacterial drugs. Doctors who educate, saying no when a prescription is a bad idea, do a greater service than those who hand out scripts too easily. Public campaigns in Australia and Scandinavia slashed antibiotic use sharply—hospital data there shows fewer superbug outbreaks.
Getting antibiotics right means stronger access to proper diagnosis and expert advice. Pharmacies investing in counseling and collaboration with prescribers close the gap. Telehealth now brings expert voices to rural or busy areas, giving more people guidance without the risks of walk-in purchasing. Tougher penalties for illegal online sales help as well. Keeping track of every prescription helps build a defense against silent resistance spreading through communities.
Spectinomycin Hydrochloride Pentahydrate isn’t just another shelf-stock medication. Prescription-only rules reflect real-world challenges. Informed prescribing, public education, safe pharmacy practices, and better access to clinical advice all form a strong line of defense. The prescription requirement isn’t about restricting choice; it’s about protecting future generations, ensuring antibiotics still work when someone really needs them.
| Names | |
| Preferred IUPAC name | (1R,2S,3S,4R,5S,6S)-5-[(Diaminomethylidene)amino]-2-[(2R,3R,5S,6S)-5-hydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-6-(hydroxymethyl)-4-methylcyclohexane-1,3,4-triol hydrochloride pentahydrate |
| Other names |
Actinospectacin Spectomycin Spectinomycinum |
| Pronunciation | /ˌspɛk.tɪˈnɒm.ɪ.sɪn haɪˌdrɒxɪˈklaɪd ˌpɛn.təˈhaɪdreɪt/ |
| Identifiers | |
| CAS Number | 22189-32-8 |
| Beilstein Reference | 3799200 |
| ChEBI | CHEBI:9178 |
| ChEMBL | CHEMBL1201202 |
| ChemSpider | 16214442 |
| DrugBank | DB00919 |
| ECHA InfoCard | 03c15ea9-468d-4120-8300-63dabad0ae15 |
| EC Number | 58-40-2 |
| Gmelin Reference | 111100 |
| KEGG | D08410 |
| MeSH | D013074 |
| PubChem CID | 65537 |
| RTECS number | WK4790000 |
| UNII | 12P83Z4HU8 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID20216860 |
| Properties | |
| Chemical formula | C14H24N2O7·HCl·5H2O |
| Molar mass | 495.89 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.676 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | -4.1 |
| Acidity (pKa) | pKa ~6.95 |
| Basicity (pKb) | 7.2 |
| Magnetic susceptibility (χ) | -64.5e-6 cm³/mol |
| Dipole moment | 3.2 ± 0.2 D |
| Pharmacology | |
| ATC code | J01GB04 |
| Hazards | |
| Main hazards | Causes eye, skin, and respiratory tract irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H319: Causes serious eye irritation. |
| Precautionary statements | P261, P264, P271, P272, P273, P280, P302+P352, P304+P340, P305+P351+P338, P308+P313, P333+P313, P337+P313, P362+P364, P391, P403+P233, P405, P501 |
| Lethal dose or concentration | LD50 (oral, rat): > 5,000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse oral LD50 = 5148 mg/kg |
| NIOSH | WX1993000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.5 mg/m³ |
| Related compounds | |
| Related compounds |
Spectinomycin Spectinomycin hydrochloride Spectinomycin sulfate Spectinomycin dihydrochloride Streptomycin Gentamicin Kanamycin Tobramycin |
